Company Overview
Snapshot
Founded in July 2014 by Irit Yaniv and Tamir Wolf, NitiNotes operates with 11–50 employees. The company has raised $32.9M across 4 funding rounds from 5 investors. In April 2026, NitiNotes announced the first commercial EndoZip procedures in Spain, marking a significant step in its market expansion.
Business overview
NitiNotes is a clinical-stage company developing a treatment for obesity, focusing on simplifying and speeding up endoscopic gastroplasty procedures. Its core product, EndoZip, is an automated and operator-independent, minimally invasive robotic suturing system designed to deliver effective restrictive sutures to the stomach wall. The company serves the medical industry, providing solutions for patients with obesity class I & II for whom traditional bariatric surgery is not an option, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.
Strategic signal
In November 2025, NitiNotes received CE Mark approval for its EndoZip system, making it the first fully automated suturing system for endoscopic sleeve gastroplasty to achieve this milestone. This approval is a critical regulatory validation, signaling to investors and the market that the company's technology meets European health and safety standards, paving the way for broader commercialization and adoption in a significant market.
Log in to access full profile ›Company Intelligence Q&A
- What is the primary product developed by NitiNotes?
- NitiNotes develops the EndoZip, an automated and operator-independent, minimally invasive robotic suturing system designed for endoscopic gastroplasty procedures to treat obesity.
- When did NitiNotes announce the first commercial procedures for EndoZip in Spain?
- In April 2026, NitiNotes announced the first commercial EndoZip procedures in Spain, indicating a significant step in its market entry and commercialization efforts.
- Has NitiNotes received any regulatory approvals for its EndoZip system?
- Yes, in November 2025, NitiNotes received CE Mark approval for its EndoZip system, making it the first fully automated suturing system for endoscopic sleeve gastroplasty to achieve this regulatory milestone.
- What was a key development for NitiNotes in December 2024?
- In December 2024, NitiNotes announced the closing of a $9.3M SAFE round, with participation from investors including Elron Ventures.
- What clinical trial progress has NitiNotes made recently?
- In December 2025, NitiNotes announced the first patient treated in the pivotal EASE clinical trial, which is evaluating the EndoZip automated suturing system for endoscopic sleeve gastroplasty.